Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338920 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
A Phase 3 study, sponsored by Currax Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
NCT03338920 is a Phase 3 study that was terminated before completion, run by Currax Pharmaceuticals. The registered enrollment target is 159 participants.
The verdict
NCT03338920, a Phase 3 study, was terminated before completion, sponsored by Currax Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.
Interventions
- DRUG Placebo
- DRUG sumatriptan nasal powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03338920
The ClinicalTrials.gov registry entry for NCT03338920 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Currax Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03338920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03338920 about?
NCT03338920 is a clinical study titled "Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents". This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.
What is the current status of trial NCT03338920?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2017-11-02. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT03338920?
The interventions under investigation include: Placebo (DRUG), sumatriptan nasal powder (DRUG).
Who is sponsoring clinical trial NCT03338920?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.